Recombinant TNFSF9 antibody
-
- Target See all TNFSF9 Antibodies
- TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))
- Antibody Type
- Recombinant Antibody
-
Reactivity
- Mouse
-
Host
- Rabbit
-
Clonality
- Chimeric
-
Conjugate
- This TNFSF9 antibody is un-conjugated
-
Application
- Western Blotting (WB), Flow Cytometry (FACS), Blocking Peptide (BP)
- Purpose
- Anti-4-1BBL [AT113-2], Rabbit IgG, kappa
- Specificity
- This antibody is specific for 4-1BB ligand (also known as CD137 ligand), which is a member of the TNF superfamily and is a type II membrane protein. 4-1BB ligand is a co-stimulatory molecule that is expressed on antigen presenting cells (DCs, monocytes/macrophages, B cells) and is upregulated upon activation of these cells. Both of the 4-1BB ligand and its receptor, TNFRSF9/4-1BB, are involved in the antigen presentation process and in the generation of cytotoxic T cells. In direct ELISAs, no cross-reactivity with recombinant human RELT is observed.
- Characteristics
-
Original Species of Ab: Rat
Original Format of Ab: IgG1
- Purification
- Protein A affinity purified
- Immunogen
- This antibody was raised by immunising LOU rats with soluble recombinant 4-1BBL:Fc fusion protein.
- Clone
- AT113-2
- Isotype
- IgG kappa
- Top Product
- Discover our top product TNFSF9 Primary Antibody
-
-
- Application Notes
- This antibody has been used in various FACS analyses, for instance, to show that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for dendritic cell-driven accumulation of antitumor cytotoxic T lymphocytes following anti-CD40 mAb treatment (French et al, 2007), to examine the underlying mechanisms of the differential T cell costimulation dependence in viral infections (Welten et al, 2015), and to explore the therapeutic benefit of using combinations of syngeneic tumor vaccines that express immune modulators (Manrique-Rincón et al, 2017). This antibody has been used as a blocking antibody, together with anti-CD70, anti-CD30L and anti-OX40L antibodies, to evaluate OX40 ligand and CD70 in the promotion of CD4+ T cell responses (Kurche et al, 2010). Furthermore, this anti-4-1BBL antibody has been used alongside the anti-CD70, anti-CD27, anti-CD40 antibodies in a BCL1-bearing mouse model to evaluate the theurapeutic potency of various combined immmunotherapies against lymphoma (French et al, 2007).
- Comment
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))
- Alternative Name
- 4-1BBL (TNFSF9 Products)
- Background
- CD137L, TNFSF9, 4-1BB ligand, 41BBL, CDw137L, homolog of mouse 4-1BB-L, receptor 4-1BB ligand, tumor necrosis factor (ligand) superfamily member 9, tumor necrosis factor (ligand) superfamily, member 9, tumor necrosis factor ligand 5A, Tumor necrosis factor ligand superfamily member 9.
- UniProt
- P41274
- Pathways
- Activated T Cell Proliferation, Cancer Immune Checkpoints
-